Search
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.
Synonyms: N-methyl-2-(2-pyridinyl)ethanamine, N-methyl-2-pyridineethanamineCategories: Heterocyclic Compounds, 1-RingVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-olFlecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawnFlecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.
Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideCategories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigationalEculizumab is a monoclonal antibody that targets complement protein C5. … [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria
Products: SOLIRIS ® 300 MGSOLUCION PARA INFUSIÓN INTRAVENOSA, ELIZARIA® 10MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓNImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. … Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidideImelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigational[L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922] … Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. … It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.
Categories: MATE 2 Inhibitors, Cytochrome P-450 SubstratesProducts: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGHuman cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalCytomegalovirus (CMV) may lead to a wide spectrum of infection in immunocompetent hosts. … As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229].
Categories: Immunoglobulin G, Human Immunoglobulin GProducts: MEGALOTECT CP SOLUTION FOR INFUSION 100 U/MLBrincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. … The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Heterocyclic Compounds, 1-RingDextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. … Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin.
Synonyms: O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine, D-thyroxine